Paige E Tucker1, Max K Bulsara2, Stuart G Salfinger3, Jason Jit-Sun Tan4, Helena Green5, Paul A Cohen6. 1. St John of God Subiaco Hospital, 12 Salvado Rd, Subiaco, WA 6008, Australia; School of Medicine, University of Notre Dame, 19 Mouat St, Fremantle, WA 6160, Australia. Electronic address: Paige.Tucker@sjog.org.au. 2. Institute for Health Research, University of Notre Dame, 19 Mouat St, Fremantle, WA 6160, Australia. Electronic address: Max.Bulsara@nd.edu.au. 3. St John of God Subiaco Hospital, 12 Salvado Rd, Subiaco, WA 6008, Australia. Electronic address: Stuart.Salfinger@health.wa.gov.au. 4. St John of God Subiaco Hospital, 12 Salvado Rd, Subiaco, WA 6008, Australia. Electronic address: Jason@womencentre.com.au. 5. Women Centre, 2 McCourt St, West Leederville, WA 6007, Australia. Electronic address: Helena@relate-sexology.com.au. 6. St John of God Subiaco Hospital, 12 Salvado Rd, Subiaco, WA 6008, Australia. Electronic address: Paul.Cohen@sjog.org.au.
Abstract
OBJECTIVES: To determine the prevalence of sexual dysfunction in women after risk-reducing salpingo-oophorectomy (RRSO) and to assess factors which may influence sexual wellbeing following this procedure. METHODS: This work is a cross-sectional study of women who underwent RRSO at a tertiary gynecologic oncology unit between January 2009 and October 2014. Data collection involved a comprehensive questionnaire including validated measures of sexual function, sexual distress, relationship satisfaction, body image, impact of event, menopause specific quality of life, and general quality of life. Participants were invited to undergo blood testing for serum testosterone and free androgen index (FAI). RESULTS: 119 of the 206 eligible women participated (58%), with a mean age of 52years. The prevalence of female sexual dysfunction (FSD) was 74% and the prevalence of hypoactive sexual desire disorder (HSDD) was 73%. Common sexual issues experienced included; lubrication difficulty (44%), reduced sexual satisfaction (41%), dyspareunia (28%) and orgasm difficulty (25%). Relationship satisfaction, the use of topical vaginal estrogen and lower generalized body pain were significantly associated with a decreased likelihood of sexual dysfunction. Serum testosterone, FAI, the use of systemic hormone replacement therapy (HRT), prior history of breast cancer, menopausal status at the time of surgery and hysterectomy did not correlate with sexual dysfunction. CONCLUSION: The prevalence of FSD and HSDD after RRSO was 74% and 73% respectively. Relationship satisfaction, low bodily pain and use of topical vaginal estrogen were associated with a lower likelihood of sexual dysfunction. There was no correlation between serum testosterone or FAI, and sexual dysfunction.
OBJECTIVES: To determine the prevalence of sexual dysfunction in women after risk-reducing salpingo-oophorectomy (RRSO) and to assess factors which may influence sexual wellbeing following this procedure. METHODS: This work is a cross-sectional study of women who underwent RRSO at a tertiary gynecologic oncology unit between January 2009 and October 2014. Data collection involved a comprehensive questionnaire including validated measures of sexual function, sexual distress, relationship satisfaction, body image, impact of event, menopause specific quality of life, and general quality of life. Participants were invited to undergo blood testing for serum testosterone and free androgen index (FAI). RESULTS: 119 of the 206 eligible women participated (58%), with a mean age of 52years. The prevalence of female sexual dysfunction (FSD) was 74% and the prevalence of hypoactive sexual desire disorder (HSDD) was 73%. Common sexual issues experienced included; lubrication difficulty (44%), reduced sexual satisfaction (41%), dyspareunia (28%) and orgasm difficulty (25%). Relationship satisfaction, the use of topical vaginal estrogen and lower generalized body pain were significantly associated with a decreased likelihood of sexual dysfunction. Serum testosterone, FAI, the use of systemic hormone replacement therapy (HRT), prior history of breast cancer, menopausal status at the time of surgery and hysterectomy did not correlate with sexual dysfunction. CONCLUSION: The prevalence of FSD and HSDD after RRSO was 74% and 73% respectively. Relationship satisfaction, low bodily pain and use of topical vaginal estrogen were associated with a lower likelihood of sexual dysfunction. There was no correlation between serum testosterone or FAI, and sexual dysfunction.
Authors: Phuong L Mai; Marion Piedmonte; Paul K Han; Richard P Moser; Joan L Walker; Gustavo Rodriguez; John Boggess; Thomas J Rutherford; Oliver Zivanovic; David E Cohn; J Tate Thigpen; Robert M Wenham; Michael L Friedlander; Chad A Hamilton; Jamie Bakkum-Gamez; Alexander B Olawaiye; Martee L Hensley; Mark H Greene; Helen Q Huang; Lari Wenzel Journal: Gynecol Oncol Date: 2017-02-10 Impact factor: 5.482
Authors: Lennart J van Winden; Ravi F M Vermeulen; Vincent van den Noort; Katja N Gaarenstroom; Gemma G Kenter; Monique M A Brood-van Zanten; Catharina M Korse; Marc van Beurden; Huub H van Rossum Journal: J Endocr Soc Date: 2022-04-25
Authors: Phuong L Mai; Helen Q Huang; Lari B Wenzel; Paul K Han; Richard P Moser; Gustavo C Rodriguez; John Boggess; Thomas J Rutherford; David E Cohn; Noah D Kauff; Kelly-Anne Phillips; Kelly Wilkinson; Robert M Wenham; Chad Hamilton; Matthew A Powell; Joan L Walker; Mark H Greene; Martee L Hensley Journal: Gynecol Oncol Date: 2019-11-21 Impact factor: 5.482
Authors: Marta Stanisz; Mariusz Panczyk; Rafał Kurzawa; Elżbieta Grochans Journal: Int J Environ Res Public Health Date: 2019-12-09 Impact factor: 3.390